System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Julien Mazieres is an expert in Oncology at Centre Hospitalier Universitaire de Toulouse (France). As of October 2026, ScienceLeadR ranks Julien Mazieres in the top 1% of experts worldwide for HER2 mutation, EGFR mutation and Bronchial Neoplasms. Julien Mazieres has authored 803 publications, the most recent in 2026, and is an investigator in 103 clinical trials, 32 of them ongoing. SLR score: 4,166 (community average: 125). How the SLR is computed.

LeadR Profile

Julien Mazieres Centre Hospitalier Universitaire de Toulouse France
4 166 ScienceLeadR Reputation 4166

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Immunology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2001 - 2026
Source: PubMed

Centre Hospitalier Universitaire de Toulouse

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 803

Citations

Citations: 56 899 1st author: 73 Last author: 100 Unique author: 3

Main journals

Ann Oncol 117
J Thorac Oncol 113
J Clin Oncol 105
Rev Mal Respir 64
Lung Cancer 38

Best Journals

Ann Oncol 60
J Clin Oncol 45
N Engl J Med 12

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.
PMID 42823821 — cells, lung, neoplasms, carcinoma, non-small-cell lung, immunotherapy, lung neoplasms, small cell lung carcinoma, therapeutics		Future Oncol20260
Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer.
PMID 42777032 — cells, lung, biological science disciplines, pharmaceutical preparations, neoplasms, lung neoplasms, therapeutics, mutation		Sci Adv20260
Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.
PMID 42679738 — cells, quality of life, lung, pain, neoplasms, drug therapy, signs and symptoms, lung neoplasms, small cell lung carcinoma, patient reported outcome measures, therapeutics, chemotherapy		Lung Cancer20260
When one-size-doesn't-fit-all: The emerging role of customized 3D stents.
PMID 42537423 — stents, constriction, pathologic, silicones, lung diseases, anatomy		Respir Med Res20260
Circulating epigenetic and epitranscriptomic biomarkers identify EGFR status, predict TKI response and reveal therapeutic vulnerabilities in NSCLC.
PMID 42477403 — cells, neoplasms, carcinoma, non-small-cell lung, nucleosomes, biomarkers, histones, therapeutics		Sci Rep20260

Clinical Studies 103

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 12

By phase:

Phase 3 43
Phase 2 30
N/A 14
Phase 2/Phase 3 6
Phase 1 5
Phase 1/Phase 2 5

By status:

Completed 52
Active not recruiting 20
Recruiting 19
Not yet recruiting 5
Terminated 5
Unknown 2

By type:

Interventional 98
Observational 5

By Monocentric/Multicentric:

monocentric 10
multicentric2to4 3
multicentric5to9 5
multicentricup10 85

Main Topics

Ongoing Clinical Trials

32 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Test How Well ZL 1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
2025-522818-23-00 — cells, lung, pharmaceutical preparations, neoplasms, lung neoplasms, small cell lung carcinoma, work, therapeutics		Phase 3Not yet recruiting2026
A Study of Navlimetostat (BMS 986504) in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First line Metastatic Non small Cell Lung Cancer with Homozygous MTAP Deletion
2025-521511-40-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, chemotherapy		Phase 2/Phase 3Recruiting2025
A multicentre Phase II single arm interventional study of neoadjuvant durvalumab and platinum based chemotherapy (CT) followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab in participants with resectable or borderline resectable stage IIB IIIB Nonsmall Cell Lung Cancer (NSCLC)
2023-503357-35-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, chemoradiotherapy, small cell lung carcinoma, chemotherapy		Phase 2Active not recruiting2024
Beamion LUNG 3 A study to test whether zongertinib helps people with surgically removed non small cell lung cancer with HER2 mutations compared with standard treatment
2025-521284-12-00 — cells, lung, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, mutation, her2 mutation		Phase 3Not yet recruiting2026
A clinical trial of V940 with or without MK 3475A in people with non small cell lung cancer (V940 014)
2025-522643-18-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma		Phase 3Not yet recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS